The number of tumor-infiltrating DCs, mature DCs expressing major histocompatibility complex (MHC) class II and activated CD103+ DCs with high expression of CD80 was identical between hIL-7/mIL-12-VV- and mIL-12-VV-treated tumors (Supplementary Fig 4). This evidence concerns the gene ITGAE and neoplasm.